Wuhan Thalys Med Tech Co Ltd (SHG:603716) — Market Cap & Net Worth
Market Cap & Net Worth: Wuhan Thalys Med Tech Co Ltd (603716)
Wuhan Thalys Med Tech Co Ltd (SHG:603716) has a market capitalization of $580.19 Million (CN¥3.96 Billion) as of August 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #11471 globally and #3223 in its home market, demonstrating a 11.07% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wuhan Thalys Med Tech Co Ltd's stock price CN¥17.56 by its total outstanding shares 225790770 (225.79 Million). See capital reinvestment ratio of Wuhan Thalys Med Tech Co Ltd to understand how much of operating cash flow is reinvested back into capital assets.
Wuhan Thalys Med Tech Co Ltd Market Cap History: 2016 to 2026
Wuhan Thalys Med Tech Co Ltd's market capitalization history from 2016 to 2026. Data shows growth from $1.18 Billion to $580.19 Million (4.93% CAGR).
Wuhan Thalys Med Tech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wuhan Thalys Med Tech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.63x
Wuhan Thalys Med Tech Co Ltd's market cap is 0.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.18 Billion | $627.33 Million | $68.92 Million | 1.88x | 17.11x |
| 2017 | $650.24 Million | $920.52 Million | $93.85 Million | 0.71x | 6.93x |
| 2018 | $625.50 Million | $1.32 Billion | $94.16 Million | 0.47x | 6.64x |
| 2019 | $555.16 Million | $1.83 Billion | $110.42 Million | 0.30x | 5.03x |
| 2020 | $544.17 Million | $2.13 Billion | $57.56 Million | 0.26x | 9.45x |
| 2021 | $475.45 Million | $2.60 Billion | -$49.51 Million | 0.18x | N/A |
| 2022 | $364.76 Million | $2.31 Billion | -$153.73 Million | 0.16x | N/A |
| 2023 | $366.42 Million | $2.01 Billion | -$158.57 Million | 0.18x | N/A |
| 2024 | $238.55 Million | $1.81 Billion | -$209.24 Million | 0.13x | N/A |
| 2025 | $678.98 Million | $1.08 Billion | -$207.28 Million | 0.63x | N/A |
Competitor Companies of 603716 by Market Capitalization
Companies near Wuhan Thalys Med Tech Co Ltd in the global market cap rankings as of August 7, 2026.
Key companies related to Wuhan Thalys Med Tech Co Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $217.92 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #166 globally with a market cap of $141.26 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #517 globally with a market cap of $51.65 Billion USD ( CN¥352.94 Billion CNY).
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #621 globally with a market cap of $43.83 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $217.92 Billion | $580.02 |
| #166 | Danaher Corporation | NYSE:DHR | $141.26 Billion | $199.98 |
| #517 | WuXi AppTec Co Ltd | SHG:603259 | $51.65 Billion | CN¥142.70 |
| #621 | IDEXX Laboratories Inc | NASDAQ:IDXX | $43.83 Billion | $590.00 |
Wuhan Thalys Med Tech Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Wuhan Thalys Med Tech Co Ltd's market cap moved from $1.18 Billion to $ 580.19 Million, with a yearly change of 4.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥580.19 Million | -14.55% |
| 2025 | CN¥678.98 Million | +184.63% |
| 2024 | CN¥238.55 Million | -34.90% |
| 2023 | CN¥366.42 Million | +0.45% |
| 2022 | CN¥364.76 Million | -23.28% |
| 2021 | CN¥475.45 Million | -12.63% |
| 2020 | CN¥544.17 Million | -1.98% |
| 2019 | CN¥555.16 Million | -11.25% |
| 2018 | CN¥625.50 Million | -3.80% |
| 2017 | CN¥650.24 Million | -44.85% |
| 2016 | CN¥1.18 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 7th, 2026 the market cap of Wuhan Thalys Med Tech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $580.19 Million USD |
| MoneyControl | $580.19 Million USD |
| MarketWatch | $580.19 Million USD |
| marketcap.company | $580.19 Million USD |
| Reuters | $580.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Wuhan Thalys Med Tech Co Ltd
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis sy… Read more